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Abstract
Morbidity and mortality have declined only modestly in patients with clinical acute lung injury
(ALI) and acute respiratory distress syndrome (ARDS), despite extensive research into the
pathophysiology. Current treatment remains primarily supportive with lung-protective ventilation
and a fluid conservative strategy. Pharmacologic therapies that reduce the severity of lung injury
in preclinical models have not yet been translated to effective clinical treatment options.
Consequently, further research in trans-lational therapies is needed. Cell-based therapy with
mesenchymal stem cells (MSCs) is one attractive new therapeutic approach. MSCs have the
capacity to secrete multiple paracrine factors that can regulate endothelial and epithelial
permeability, decrease inflammation, enhance tissue repair, and inhibit bacterial growth. This
review will focus on recent studies, which support the potential therapeutic use of MSCs in ALI/
ARDS, with an emphasis on the role of paracrine soluble factors.
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Introduction
Adult stem cells are tissue specific cells that have retained the ability to differentiate into a
distinct variety of cell lineages and have self-renewal capability. Although adult stem cells
do not possess the full plasticity of embryonic stem cells (ESCs), they offer practical
advantages including ease of isolation and propagation. More significantly, they have a
limited risk of tumor formation and are not associated with the ethical controversy that
surrounds ESC research. Mesenchymal stem cells (MSCs) are one class of adult stem cells
that have generated a significant amount of interest as a potential therapy for lung disease.
MSCs were first discovered in 1968 by Friedenstein et al. [1], who found bone marrow
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stromal cells that were adherent, clonogenic, and fibroblastic in appearance. MSCs, also
called multipotent mesenchymal stromal cells, can now be isolated from a variety of human
tissues including the bone marrow, adipose tissue, and placenta. Bone marrow-derived
MSCs reside near the sinusoids and function as support cells for hematopoietic stem cells.
Although MSCs comprise less than 0.1% of all bone marrow cells, they can be isolated from
whole bone marrow aspirates by their ability to adhere to plastic and form colonies.
Although no unique MSC surface markers have been identified, the International Society of
Cellular Therapy defined MSCs in 2006 by three criteria: (1) MSCs must be adherent to
plastic under standard tissue culture conditions; (2) MSCs must express certain cell surface
markers such as CD73, CD90, and CD105, but must not express other markers including
CD45, CD34, CD14, or CD11b; and (3) MSCs must have the capacity to differentiate into
mesenchymal lineages including osteoblasts, adipocytes, and chrondoblasts under in vitro
conditions [2].
The current enthusiasm surrounding the potential use of MSCs for therapeutic purposes is
based on their low immunogenicity, their immunomodulatory properties, and their ability to
secrete endothelial and epithelial growth factors and, more recently, antimicrobial peptides
(Table 1). Allogeneic MSCs are able to evade clearance by the host immune system through
a variety of mechanisms including low expression of the major histocompatibility complex
(MHC) I and II proteins as well as lack of the T-cell costimulatory molecules, CD80 and
CD86, a characteristic of MSCs often referred to as being “immunoprivileged” [13]. MHC II
molecules are designed to enable T4-lymphocytes to recognize epitopes of exogenous
antigens and discriminate self from nonself. This property makes MSCs attractive for cell-
based therapy because they can be administered to patients without human leukocyte antigen
matching. However, recent studies have shown that MSCs can express higher levels of the
MHC class II proteins than originally thought [14–16]. In addition, Nauta et al. [17]
demonstrated that infusion of allogeneic MSCs elicited a host response and led to graft
rejection. It has now become apparent that the original belief that MSCs have low
immunogenicity due to a lack of MHC II antigen is not entirely correct. However, the
concern over the potential immunogenicity of MSCs must be interpreted in light of how
MSCs affect both the innate and adaptive immune systems, often suppressing T and B
lymphocyte activations (see below). Although these are different issues and seem to have
opposing functions, they clearly affect each other’s behavior in vivo and must be studied
further.
Mscs in Preclinical Ali Models
Previous studies suggested that bone marrow-derived MSCs may have therapeutic
applications in several clinical disorders including myocardial infarction [18–21], diabetes
[22], sepsis [9, 11], hepatic failure [23], and acute renal failure [24]. Bone marrow-derived
MSCs have been investigated in several in vivo models of lung disease [5, 8–10, 25–30]. In
a mouse model of bleomycin-induced lung injury and fibrosis, syngeneic MSCs improved
survival and lung inflammation when given intravenously [25, 27]. In a follow-up study,
Ortiz et al. [8] found that a subpopulation of mouse MSC produced interleu-kin-1 receptor
antagonist (IL-1ra) that was capable of attenuating the severity of bleomycin-induced lung
injury. To determine the effect of MSCs on lung injury from endotoxin, several groups
studied the therapeutic effect of MSCs following intraperitoneal [28] or intratracheal
Escherichia coli endotoxin [5, 30] in mice. Xu et al. [28] found that intravenous
administration of syngeneic MSCs following intraperitoneal lipopolysac-charide (LPS)
prevented endotoxin-induced pulmonary inflammation, injury, and edema as well as the
influx of neutrophils into the injured alveoli. In addition, Xu et al. [30] and Mei et al. [5]
also discovered that transfection of mouse MSCs with and without human angiopoietin-1
(Ang-1) both reduced the severity of E. coli endotoxin-induced lung injury. In all these
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studies, the therapeutic effect could not be accounted for by the level of lung MSC
engraftment, suggesting the importance of paracrine soluble factors or direct interaction with
host cells.
One major limitation to these studies was that MSCs were not used as a treatment modality;
the cells were given concurrent with the injury or before the injury. Recently, we reported
that intrabronchial instillation of syngeneic MSCs 4 hours after endotoxin delivery to the
lung improved survival and reduced the extent of pulmonary edema formation in E. coli
endotoxin-induced acute lung injury (ALI) in mice [10]. To further define the therapeutic
potential of MSCs, we developed two human models of ALI: an ex vivo human lung
preparation perfused with human blood and injured by E. coli endotoxin and primary
cultures of human alveolar epithelial type II cells grown in a Transwell plate with an air-
liquid interface injured by an inflammatory insult. In the ex vivo perfused human lung, the
intrabronchial instillation of human MSCs 1 hour after endotoxin-induced lung injury
restored alveolar fluid clearance (AFC) or the ability to resolve pulmonary edema fluid in
part by the secretion of keratinocyte growth factor (KGF) [3]. In primary cultures of human
alveolar type II cells, human MSCs grown without cell contact in a Transwell plate restored
the increase in epithelial permeability to protein caused by exposure to inflammatory
cytokines in part by the secretion of Ang-1 [6]. In addition, new preliminary data from a
meeting suggest that MSCs may enhance repair to the injured alveolar epithelium in a LPS-
induced lung injury model in rats by the mitochondrial transfer of material from one cell to
the other [31]. In summary, these studies supported the theme that MSC paracrine factors
with or without direct interaction with injured lung cells were a key mechanism by which
MSCs promoted repair in the injured tissue beds.
Mechanism: Engraftment
Much of the initial interest in adult stem cell therapy originated from the multipotent nature
of the bone marrow-derived cells. Krause et al. [32] found that a single bone marrow-
derived hematopoietic stem cell could give rise to cells of multiple different organs
including the lung. She reported up to 20% engraftment of bone marrow-derived cells in the
lung, including epithelial cells, from a single hematopoietic precursor. This report stimulated
additional investigations into the possibility that bone marrow-derived MSCs might be able
to regenerate the lung epithelium and/or endothelium as well. However, these results were
questioned by multiple groups, who observed only engraftment of leukocyte lineages [33] or
low engraftment rates in lung injury models with observed rates of <1% [25, 27, 34, 35].
Despite initial interest in their multipotent properties, engraftment in the lung now does not
appear to play the major beneficial role. The beneficial effect of MSCs appears to derive
more from their capacity to home to injured tissue beds, interact with injured host cells, and
secrete paracrine soluble factors that modulate immune responses as well as alter the
responses of endothelium or epithelium to injury through the release of growth factors and
antimicrobial peptides [3, 6, 8, 9, 12].
However, the role of stem cell engraftment in repair following lung injury requires further
research. Sueblinvong et al. [36] found that human umbilical cord MSCs when cultured in
vitro with specialized growth medium expressed Clara cell secretory protein (CCSP),
surfactant protein-C (SP-C), and cystic fibrosis transmembrane conductance regulator
(CFTR), important functional markers of lung alveolar epithelial cells. After systemic
administration to immunotolerant, nonobese diabetic/severe combined immunodeficiency
mice, rare cells were localized in the lung airway epithelium that expressed cytokeratin and
human CFTR. Wong et al. [37, 38] found a subpopulation of adherent human and murine
bone marrow cells that expressed CCSP as well, and when cultured ex vivo with an air-
liquid interface, these CCSP+ cells expressed alveolar type I and II markers such as pro-SP-
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C, CFTR, and epithelial sodium channel (ENaC). CCSP+ cells preferentially homed to
naphthalene-damaged airways when delivered transtracheally or intravenously. Although
further research is needed, these publications highlight the potential of in vitro modification
of MSCs, which may increase lung engraftment and/or regeneration in vivo.
Several groups have also identified adult stem cells within the lung, some with the features
of MSCs. Kim et al. [39] identified CCSP+ SP-C+ Sca-1 CD34 cells at the bronchoalveolar
ductal junction in mice,+which were + capable of differentiating into Clara cells or alveolar
type I or II in response to lung injury. In addition, fibroblast-like cells have been found in
the lungs of premature human infants as well as the lungs of human allograft following lung
transplantation, which have characteristics of MSCs [40, 41]. Jarvinen et al. [41]
demonstrated that these lung resident MSCs from human lung allografts, similar to bone
marrow-derived MSCs, suppressed T-cell activation in vitro, primarily through the secretion
of prostaglandin E2 (PGE2). Although promising, the roles of these lung resident stem cells
during ALI will need to be investigated further. One potential mechanism of benefit by MSC
therapy in ALI may be through the support of these endogenous stem cells.
Mechanism: Immunomodulation
A major characteristic of MSCs has been the immunomodulatory properties of the cells.
Multiple studies have demonstrated that MSCs possess potent immunosuppressive effects by
inhibiting the activity of both innate and adaptive immune cells [42–45]. This
immunosuppression has been shown to be mediated by cell contact-dependent and cell
contact-independent mechanisms through the release of soluble factors. The list of candidate
mediators released or induced by MSCs include transforming growth factor-b, tumor
necrosis factor a (TNFα)–stimulated gene/protein 6 (TSG-6) [21], PGE2, indoleamine 2,3-
dioxygenase, interleukin-10 (IL-10), and IL-1ra among others. In a model of sepsis
following cecal ligation and puncture (CLP) in mice, Nemeth et al. [9] found that bone
marrow-derived mouse MSCs, activated by LPS or TNFα, secreted PGE2, which
reprogrammed alveolar macrophages to secrete IL-10. The beneficial effect of MSCs on
mortality and improved organ function following sepsis was eliminated by macrophage
depletion or pretreatment with antibodies to IL-10 or the IL-10 receptor, suggesting an
essential role for IL-10 in these experiments; IL-10 is a cytokine secreted predominantly by
monocytes that downregulates the expression of T helper 1 cytokines, MHC class II
antigens, and costimulatory molecules on macrophages. IL-10 has also been reported to
inhibit the rolling, adhesion, and transepithelial migration of neutrophils [46] (Fig. 1).
In a model of ALI following intrabronchial E. coli endotoxin in mice, we [11] found that
syngeneic MSCs improved survival and lung injury in association with a decrease in
macrophage inflammatory protein-2 and TNFα levels in the bronchoalveolar lavage (BAL)
fluid and elevated levels of IL-10 in both the plasma and BAL fluids. In bleomycin-induced
lung injury and fibrosis in mice, Ortiz et al. [8] found that mouse MSCs decreased
subsequent lung collagen accumulation, fibrosis, and levels of matrix metalloproteinases in
part by IL-1ra secretion; IL-1ra is a cytokine that competitively competes with IL-1b for
IL-1 receptor binding. IL-1b is one of the major inflammatory cytokines in pulmonary
edema fluid in patients with ALI/acute respiratory distress syndrome (ARDS) [47]. These
studies confirmed the anti-inflammatory effect of MSCs in multiple lung injury experiments
in mice [5, 25, 27, 28, 30].
Despite the well documented anti-inflammatory effects of MSCs, recent literature described
a dual role for MSCs as an immunostimulatory cell as well [16]. Several investigators have
reported that MSCs can upregulate expression of MHC II when exposed to low levels of
inflammation and function as antigen-presenting cells stimulating the adaptive immune
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system [14, 15]. Recent evidence has also shown that MSCs can secrete IL-6 and induce
production of IgG by B lymphocytes in an in vitro setting [48]. In addition, MSCs can
prevent neutrophil apoptosis and degranulation in culture without inhibiting their phagocytic
or chemotactic capabilities [49]. Thus, MSCs have more complex effects on the immune
system than their classical role as immune suppressor cells. In the future, we will have to
study the complex and often opposing relationship between the potential immunogenicity of
MSCs and their ability to suppress the innate and adaptive immunity to understand the
significance of immunomodulation during therapy for lung injury.
Mechanism: Afc
Impaired AFC (i.e., the resolution of pulmonary edema) is common in patients with ALI/
ARDS. The level of AFC impairment has significant prognostic value in determining
morbidity and mortality [50, 51]. Several experimental studies have studied the mechanisms
that reduce AFC in ALI, and several pathways have been implicated [52, 53]. In ALI, we
and other investigators have reported that pulmonary edema fluid contained high levels of
several proinflammatory cytokines, including IL-1b, IL-8, TNFα, and TGFb1 [54–56].
Several of these proinflammatory cytokines have been studied in experimental epithelial
fluid transport experiments, particularly the effect of the inflammatory cytokines on the
major sodium channel (ENaC a, b, and c) and sodium-potassium ATPase (Na-K-ATPase),
and CFTR, alveolar epithelial proteins involved in fluid transport or pulmonary edema
resolution.
Bone marrow-derived MSCs are known to produce several epithelial specific growth
factors, specifically KGF, the seventh member of the fibroblast growth factor (FGF) family.
We have been particularly interested in KGF because multiple investigators have reported
that KGF can reduce lung injury in small animal models of pulmonary edema. Recombinant
human KGF pretreatment reduced mortality following intratracheal instillation of
hydrochloric acid [57, 58], bleomycin [59, 60], hyperoxia [61, 62], and Pseudomonas
aeruginosa [63]. In rat lung, KGF improved alveolar fluid transport in part by upregulating
aENaC gene expression [64] and Na-K-ATPase activity [65]. In the ex vivo perfused human
lung, the intrabronchial instillation of human MSCs 1 hour after endotoxin-induced lung
injury restored AFC in part by the secretion of KGF [3], which increased vectorial fluid
transport across the alveolar epithelium in part through increased trafficking of sodium
transport proteins to the cell surface [66, 67]. These studies demonstrated how MSCs may
reduce pulmonary edema, a key pathological feature in ALI with prognostic significance
(Fig. 1).
Mechanism: Lung Protein Permeability
The integrity of the lung microvascular endothelium is essential to prevent the influx of
protein-rich fluid from the plasma as well as inflammatory cells, which may further
aggravate the ability of the lung epithelium to reduce alveolar edema. Several MSC
paracrine soluble factors, such as Ang-1 and KGF, are potentially important in these effects.
Ang-1, a ligand for the endothelial Tie2 receptor, is a known endothelial survival [68] and
vascular stabilization factor that reduces endothelial permeability and inhibits leukocyte-
endothelium interactions by modifying endothelial cell adhesion molecules and cell
junctions [69–72]. We recently found that allogeneic human MSCs secreted a significant
amount of Ang-1. Using small interfering RNA knockdown, the secretion of Ang-1 was
essential to prevent the increase in epithelial protein permeability in primary cultures of
human alveolar epithelial type II cells injured by an inflammatory insult [6]. The effect of
MSCs secreted Ang-1 in lung permeability supported several recent studies, which
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demonstrated the therapeutic use of MSCs (with and without transfection with human
Ang-1) in mice injured by LPS [5, 7, 30] (Fig. 1).
The potential therapeutic role of KGF is intriguing given the recent study by Murakami et al.
[4] that reported that FGFs FGF2, FGF4, and FGF8, which are specific for both FGF
receptors 1IIIc and 3IIIc, are responsible for the maintenance of endothelial barrier
homeostasis. In models of acute permeability edema such as α-naphthylthiourea [65, 73], P.
aeruginosa [63], or ventilator-induced lung injury [74], KGF reduced lung edema and BAL
protein levels. Another epithelial specific growth factor secreted by MSCs is hepatocyte
growth factor (HGF). Previously, HGF was found to stabilize integrity of pulmonary
endothelial cells by the inhibition of Rho GTPase and the prevention of actin stress fiber
formation and paracellular gaps among pulmonary endothelial cells injured by thrombin [75,
76]. The effect of MSC-derived growth factors on restoring or maintaining lung
permeability following injury is promising and will need to be studied further.
Mechanism: Antibacterial Properties
One safety concern with MSC-based therapy, particularly in treating ALI/ARDS, is their
effect on host defense against bacterial infection. Bacterial pneumonia and sepsis from a
nonpulmonary cause are two of the most common etiologies of ARDS [77]. Given the
preponderance of literature that describes the immunosuppressive effect of MSCs, there was
a concern that this effect might diminish host defense against infections. However, recent in
vivo studies have provided evidence for the beneficial effects of MSCs in the treatment of
bacteria-induced sepsis. In the mouse model of sepsis (CLP), intravenous syngeneic MSCs
reduced mortality, improved organ function, and decreased total bacterial counts in the
blood and peritoneal fluid [9]. Survival benefits in this study were explained in part by the
immunomodulatory properties of MSCs mediated by soluble paracrine factors such as IL-10
and PGE2. In another study, Gonzalez-Rey et al. [78] reported the protective effect of
subcutaneous adipose tissue-derived human and mouse MSCs in mouse experimental colitis
and sepsis, which also was associated with improved bacterial clearance. Intraperitoneal
MSC treatment suppressed acute inflammatory autoimmune responses in mice by inhibiting
the inflammatory and Th1 responses. However, the actual mechanism of enhanced bacterial
clearance was not clearly identified in these studies.
Macrophages and monocytes play a central role in the production of inflammatory mediators
during sepsis, and they appear to be a major cell target in the protective effect of MSCs.
Recently, Mei et al. [11] reported that the improvement in bacterial clearance in syngeneic
MSC-treated septic mice following CLP could be in part explained by enhanced phagocytic
activity of splenic monocytes and macrophages. Also, Kim and Hematti [79] reported that
human MSCs improved phagocytic activity of monocyte-derived macrophages, when
cocultured in vitro. They demonstrated that coculture of human MSCs and macrophages
caused an alternative state (M2) of macrophage activation, which is characterized by anti-
inflammatory properties and more potent phagocytic activity. The molecular mechanism of
such macrophage “reprogramming” effect of MSCs in both of these studies is unclear.
Interestingly, Mei et al. did not find any effect of MSCs on phagocytic activity of
macrophages in vitro coculture experiments, but clearly demonstrated enhancement of
phagocytosis in CD11+ cell population isolated from mouse spleen after MSCs treatment.
It is now well-established that MSCs have Toll-like and formyl peptide-like receptors and
become activated in response to different bacterial products, suggesting the possibility that
MSCs may be directly involved in innate immune response [10, 80]. Recently, we found that
human bone marrow-derived MSCs can inhibit bacterial growth directly, and their
antimicrobial effect is mediated in part through the secretion of an antimicrobial peptide
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LL-37, which was upregulated upon bacterial stimulation [12]. We also demonstrated that
LL-37 secretion by MSCs improved bacterial clearance in vivo in the mouse model of E.
coli pneumonia, when MSCs were administered intrabronchially. These antimicrobial
activities of MSCs suggest these cells may participants in host defense (Fig. 1).
Conclusion
ALI/ARDS is the most common cause of acute hypoxemic respiratory failure in critically ill
patients [77, 81]. Current treatment for ALI/ARDS is only supportive [82, 83], and
therefore, new treatments are needed. Recently, multiple investigators have demonstrated
the beneficial effects of MSCs in preclinical models of ALI in both rodents and human
tissue. Given the promising initial results, there has been enthusiasm to advance MSCs and/
or cell-based therapy to patients with ALI/ARDS [84]. Currently, there are over 120 clinical
trials registered with clinicaltrial.gov involving the use of MSCs as therapy in patients with
cardiac, renal, and autoimmune diseases. Much of current interest of MSCs have focused on
soluble factors due to their ability to secrete multiple paracrine factors such as growth
factors, factors regulating endothelial and epithelial permeability, anti-inflammatory
cytokines, and, more recently, antimicrobial peptides that can potentially treat the major
abnormalities that underlie ALI, including impaired AFC, altered lung endothelial
permeability, dysregulated inflammation, and infection. However, given the recent findings
of in vitro modification of these MSCs to a lung epithelial phenotype and the potential to
increase lung engraftment in vivo [36, 37] and the discovery of endogenous adult lung stem
cells with features of MSCs [39, 41], further mechanistic studies are needed to maximize
MSCs therapeutic effect. At a minimum, issues of potency (“what defines a MSCs”) and
immunogenicity versus immunomodulatory behavior of MSCs needs further work. For
instance, the effect of culture conditions on both MSCs growth and phenotype is significant
but still not fully appreciated [85]; not all MSCs retain their “stem” cell-like properties in
culture. It may be time to revise the definition of MSCs set forth by the International Society
of Cellular Therapy from 2006 [2] to compare preclinical animal studies and clinical trials
for efficacy better. Regardless, future research in this field should continue and focus on
elucidating the basic mechanisms responsible for the beneficial effects of MSCs. In the
process, a novel and safe therapy for ALI/ARDS might eventually emerge.
Acknowledgments
We thank Diana Lim for her excellent help in preparing the figure. This work was supported by the National
Institutes of Health, National Heart, Lung, and Blood Institute (NHLBI 093026 and NHLBI 5185651854 [to
J.W.L.]) and the National Institutes of Health, National Institute of Allergy and Infectious Diseases (NIAID
A1053194 [to M.A.M.]). Pediatric Scientist NIH (James P Howard).
REFERENCES
1. Friedenstein AJ, Petrakova KV, Kurolesova AI, et al. Heterotopic of bone marrow. Analysis of
precursor cells for osteogenic and hematopoietic tissues. Transplantation. 1968; 6:230–247.
[PubMed: 5654088]
2. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal
stromal cells. The international society for cellular therapy position statement. Cytotherapy. 2006;
8:315–317. [PubMed: 16923606]
3. Lee JW, Fang X, Gupta N, et al. Allogeneic human mesenchymal stem cells for treatment of E. coli
endotoxin-induced acute lung injury in the ex vivo perfused human lung. Proc Natl Acad Sci USA.
2009; 106:16357–16362. [PubMed: 19721001]
4. Murakami M, Nguyen LT, Zhang ZW, et al. The FGF system has a key role in regulating vascular
integrity. J Clin Invest. 2008; 118:3355–3366. [PubMed: 18776942]
Lee et al. Page 7
Stem Cells. Author manuscript; available in PMC 2012 June 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
5. Mei SH, McCarter SD, Deng Y, et al. Prevention of LPS-induced acute lung injury in mice by
mesenchymal stem cells overexpressing angiopoietin 1. PLoS Med. 2007; 4:e269. [PubMed:
17803352]
6. Fang X, Neyrinck AP, Matthay MA, et al. Allogeneic human mesenchymal stem cells restore
epithelial protein permeability in cultured human alveolar type ii cells by secretion of
angiopoietin-1. J Biol Chem. 2010; 285:26211–26222. [PubMed: 20554518]
7. McCarter SD, Mei SH, Lai PF, et al. Cell-based angiopoietin-1 gene therapy for acute lung injury.
Am J Respir Crit Care Med. 2007; 175:1014–1026. [PubMed: 17322110]
8. Ortiz LA, Dutreil M, Fattman C, et al. Interleukin 1 receptor antagonist mediates the
antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl
Acad Sci USA. 2007; 104:11002–11007. [PubMed: 17569781]
9. Nemeth K, Leelahavanichkul A, Yuen PS, et al. Bone marrow stromal cells attenuate sepsis via
prostaglandin e(2)-dependent reprogramming of host macrophages to increase their interleukin-10
production. Nat Med. 2009; 15:42–49. [PubMed: 19098906]
10. Gupta N, Su X, Popov B, et al. Intrapulmonary delivery of bone marrow-derived mesenchymal
stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. J
Immunol. 2007; 179:1855–1863. [PubMed: 17641052]
11. Mei SH, Haitsma JJ, Dos Santos CC, et al. Mesenchymal stem cells reduce inflammation while
enhancing bacterial clearance and improving survival in sepsis. Am J Respir Crit Care Med.
182:1047–1057. [PubMed: 20558630]
12. Krasnodembskaya A, Song Y, Fang X, et al. Antibacterial effect of human mesenchymal stem cells
is mediated in part from secretion of the antimicrobial peptide LL-37. Stem Cells. 2010; 28:2229–
2238. [PubMed: 20945332]
13. Patel SA, Sherman L, Munoz J, et al. Immunological properties of mesenchymal stem cells and
clinical implications. Arch Immunol Ther Exp (Warsz). 2008; 56:1–8. [PubMed: 18250975]
14. Chan JL, Tang KC, Patel AP, et al. Antigen-presenting property of mesenchymal stem cells occurs
during a narrow window at low levels of interferon-gamma. Blood. 2006; 107:4817–4824.
[PubMed: 16493000]
15. Stagg J, Pommey S, Eliopoulos N, et al. Interferon-gamma-stimulated marrow stromal cells: A
new type of nonhematopoietic antigen-presenting cell. Blood. 2006; 107:2570–2577. [PubMed:
16293599]
16. Stagg J. Immune regulation by mesenchymal stem cells: Two sides to the coin. Tissue Antigens.
2007; 69:1–9. [PubMed: 17212702]
17. Nauta AJ, Westerhuis G, Kruisselbrink AB, et al. Donor-derived mesenchymal stem cells are
immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative
setting. Blood. 2006; 108:2114–2120. [PubMed: 16690970]
18. Li TS, Hayashi M, Ito H, et al. Regeneration of infarcted myocardium by intramyocardial
implantation of ex vivo transforming growth factor-beta-preprogrammed bone marrow stem cells.
Circulation. 2005; 111:2438–2445. [PubMed: 15883211]
19. Miyahara Y, Nagaya N, Kataoka M, et al. Monolayered mesenchymal stem cells repair scarred
myocardium after myocardial infarction. Nat Med. 2006; 12:459–465. [PubMed: 16582917]
20. Iso Y, Spees JL, Serrano C, et al. Multipotent human stromal cells improve cardiac function after
myocardial infarction in mice without long-term engraftment. Biochem Biophys Res Commun.
2007; 354:700–706. [PubMed: 17257581]
21. Lee RH, Pulin AA, Seo MJ, et al. Intravenous HMSCs improve myocardial infarction in mice
because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell
Stem Cell. 2009; 5:54–63. [PubMed: 19570514]
22. Lee RH, Seo MJ, Reger RL, et al. Multipotent stromal cells from human marrow home to and
promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. Proc Natl Acad
Sci USA. 2006; 103:17438–17443. [PubMed: 17088535]
23. Parekkadan B, van Poll D, Suganuma K, et al. Mesenchymal stem cell-derived molecules reverse
fulminant hepatic failure. PLoS One. 2007; 2:e941. [PubMed: 17895982]
Lee et al. Page 8
Stem Cells. Author manuscript; available in PMC 2012 June 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
24. Togel F, Hu Z, Weiss K, et al. Administered mesenchymal stem cells protect against ischemic
acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol.
2005; 289:F31–F42. [PubMed: 15713913]
25. Ortiz LA, Gambelli F, McBride C, et al. Mesenchymal stem cell engraftment in lung is enhanced
in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci USA.
2003; 100:8407–8411. [PubMed: 12815096]
26. Yamada M, Kubo H, Kobayashi S, et al. Bone marrow-derived progenitor cells are important for
lung repair after lipopolysaccharide-induced lung injury. J Immunol. 2004; 172:1266–1272.
[PubMed: 14707105]
27. Rojas M, Xu J, Woods CR, et al. Bone marrow-derived mesenchymal stem cells in repair of the
injured lung. Am J Respir Cell Mol Biol. 2005; 33:145–152. [PubMed: 15891110]
28. Xu J, Woods CR, Mora AL, et al. Prevention of endotoxin-induced systemic response by bone
marrow-derived mesenchymal stem cells in mice. Am J Physiol Lung Cell Mol Physiol. 2007;
293:L131–L141. [PubMed: 17416739]
29. Zhen G, Liu H, Gu N, et al. Mesenchymal stem cells transplantation protects against rat pulmonary
emphysema. Front Biosci. 2008; 13:3415–3422. [PubMed: 18508443]
30. Xu J, Qu J, Cao L, et al. Mesenchymal stem cell-based angiopoietin-1 gene therapy for acute lung
injury induced by lipopolysaccharide in mice. J Pathol. 2008; 214:472–481. [PubMed: 18213733]
31. Islam MN, Otsu K, Houser SD, et al. Mitochondrial donation by mesenchymal stromal cells
rescues alveolar surfactant secretion in sepsis. FASEB J. 2010; 24:612–24.
32. Krause DS, Theise ND, Collector MI, et al. Multi-organ, multi-lineage engraftment by a single
bone marrow-derived stem cell. Cell. 2001; 105:369–377. [PubMed: 11348593]
33. Wagers AJ, Sherwood RI, Christensen JL, et al. Little evidence for developmental plasticity of
adult hematopoietic stem cells. Science. 2002; 297:2256–2259. [PubMed: 12215650]
34. Kotton DN, Fabian AJ, Mulligan RC. Failure of bone marrow to reconstitute lung epithelium. Am
J Respir Cell Mol Biol. 2005; 33:328–334. [PubMed: 15961722]
35. Loi R, Beckett T, Goncz KK, et al. Limited restoration of cystic fibrosis lung epithelium in vivo
with adult bone marrow-derived cells. Am J Respir Crit Care Med. 2006; 173:171–179. [PubMed:
16179642]
36. Sueblinvong V, Loi R, Eisenhauer PL, et al. Derivation of lung epithelium from human cord
blood-derived mesenchymal stem cells. Am J Respir Crit Care Med. 2008; 177:701–711.
[PubMed: 18063840]
37. Wong AP, Dutly AE, Sacher A, et al. Targeted cell replacement with bone marrow cells for airway
epithelial regeneration. Am J Physiol Lung Cell Mol Physiol. 2007; 293:L740–L752. [PubMed:
17616650]
38. Wong AP, Keating A, Lu WY, et al. Identification of a bone marrow-derived epithelial-like
population capable of repopulating injured mouse airway epithelium. J Clin Invest. 2009;
119:336–348. [PubMed: 19164856]
39. Kim CF, Jackson EL, Woolfenden AE, et al. Identification of bron-chioalveolar stem cells in
normal lung and lung cancer. Cell. 2005; 121:823–835. [PubMed: 15960971]
40. Hennrick KT, Keeton AG, Nanua S, et al. Lung cells from neonates show a mesenchymal stem cell
phenotype. Am J Respir Crit Care Med. 2007; 175:1158–1164. [PubMed: 17332484]
41. Jarvinen L, Badri L, Wettlaufer S, et al. Lung resident mesenchymal stem cells isolated from
human lung allografts inhibit T cell proliferation via a soluble mediator. J Immunol. 2008;
181:4389–4396. [PubMed: 18768898]
42. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell
responses. Blood. 2005; 105:1815–1822. [PubMed: 15494428]
43. Beyth S, Borovsky Z, Mevorach D, et al. Human mesenchymal stem cells alter antigen-presenting
cell maturation and induce T-cell unre-sponsiveness. Blood. 2005; 105:2214–2219. [PubMed:
15514012]
44. Corcione A, Benvenuto F, Ferretti E, et al. Human mesenchymal stem cells modulate B-cell
functions. Blood. 2006; 107:367–372. [PubMed: 16141348]
45. Glennie S, Soeiro I, Dyson PJ, et al. Bone marrow mesenchymal stem cells induce division arrest
anergy of activated T cells. Blood. 2005; 105:2821–2827. [PubMed: 15591115]
Lee et al. Page 9
Stem Cells. Author manuscript; available in PMC 2012 June 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
46. Ajuebor MN, Das AM, Virag L, et al. Role of resident peritoneal macrophages and mast cells in
chemokine production and neutrophil migration in acute inflammation: Evidence for an inhibitory
loop involving endogenous IL-10. J Immunol. 1999; 162:1685–1691. [PubMed: 9973430]
47. Geiser T, Atabai K, Jarreau PH, et al. Pulmonary edema fluid from patients with acute lung injury
augments in vitro alveolar epithelial repair by an IL-1beta-dependent mechanism. Am J Respir
Crit Care Med. 2001; 163:1384–1388. [PubMed: 11371405]
48. Rasmusson I, Le Blanc K, Sundberg B, et al. Mesenchymal stem cells stimulate antibody secretion
in human B cells. Scand J Immunol. 2007; 65:336–343. [PubMed: 17386024]
49. Raffaghello L, Bianchi G, Bertolotto M, et al. Human mesenchymal stem cells inhibit neutrophil
apoptosis: A model for neutrophil preservation in the bone marrow niche. Stem Cells. 2008;
26:151–162. [PubMed: 17932421]
50. Matthay MA, Wiener-Kronish JP. Intact epithelial barrier function is critical for the resolution of
alveolar edema in humans. Am Rev Respir Dis. 1990; 142(6 pt 1):1250–1257. [PubMed: 2252240]
51. Ware LB, Matthay MA. Alveolar fluid clearance is impaired in the majority of patients with acute
lung injury and the acute respiratory distress syndrome. Am J Respir Crit Care Med. 2001;
163:1376–1383. [PubMed: 11371404]
52. Matthay MA, Folkesson HG, Clerici C. Lung epithelial fluid transport and the resolution of
pulmonary edema. Physiol Rev. 2002; 82:569–600. [PubMed: 12087129]
53. Folkesson HG, Matthay MA. Alveolar epithelial ion and fluid transport: Recent progress. Am J
Respir Cell Mol Biol. 2006; 35:10–19. [PubMed: 16514116]
54. Pugin J, Verghese G, Widmer MC, et al. The alveolar space is the site of intense inflammatory and
profibrotic reactions in the early phase of acute respiratory distress syndrome. Crit Care Med.
1999; 27:304–312. [PubMed: 10075054]
55. Olman MA, White KE, Ware LB, et al. Pulmonary edema fluid from patients with early lung
injury stimulates fibroblast proliferation through IL-1 beta-induced IL-6 expression. J Immunol.
2004; 172:2668–2677. [PubMed: 14764742]
56. Lee JW, Fang X, Dolganov G, et al. Acute lung injury edema fluid decreases net fluid transport
across human alveolar epithelial type II cells. J Biol Chem. 2007; 282:24109–24119. [PubMed:
17580309]
57. Nemzek JA, Ebong SJ, Kim J, et al. Keratinocyte growth factor pretreatment is associated with
decreased macrophage inflammatory protein-2alpha concentrations and reduced neutrophil
recruitment in acid aspiration lung injury. Shock. 2002; 18:501–506. [PubMed: 12462556]
58. Yano T, Deterding RR, Simonet WS, et al. Keratinocyte growth factor reduces lung damage due to
acid instillation in rats. Am J Respir Cell Mol Biol. 1996; 15:433–442. [PubMed: 8879176]
59. Sugahara K, Iyama K, Kuroda MJ, et al. Double intratracheal instillation of keratinocyte growth
factor prevents bleomycin-induced lung fibrosis in rats. J Pathol. 1998; 186:90–98. [PubMed:
9875145]
60. Yi ES, Salgado M, Williams S, et al. Keratinocyte growth factor decreases pulmonary edema,
transforming growth factor-beta andplatelet-derived growth factor-BB expression, and alveolar
type II cell loss in bleomycin-induced lung injury. Inflammation. 1998; 22:315–325. [PubMed:
9604718]
61. Barazzone C, Donati YR, Rochat AF, et al. Keratinocyte growth factor protects alveolar epithelium
and endothelium from oxygen-induced injury in mice. Am J Pathol. 1999; 154:1479–1487.
[PubMed: 10329601]
62. Panos RJ, Bak PM, Simonet WS, et al. Intratracheal instillation of keratinocyte growth factor
decreases hyperoxia-induced mortality in rats. J Clin Invest. 1995; 96:2026–2033. [PubMed:
7560096]
63. Viget NB, Guery BP, Ader F, et al. Keratinocyte growth factor protects against Pseudomonas
aeruginosa-induced lung injury. Am J Physiol Lung Cell Mol Physiol. 2000; 279:L1199–L1209.
[PubMed: 11076810]
64. Wang Y, Folkesson HG, Jayr C, et al. Alveolar epithelial fluid transport can be simultaneously
upregulated by both KGF and beta-agonist therapy. J Appl Physiol. 1999; 87:1852–1860.
[PubMed: 10562630]
Lee et al. Page 10
Stem Cells. Author manuscript; available in PMC 2012 June 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
65. Guery BP, Mason CM, Dobard EP, et al. Keratinocyte growth factor increases transalveolar
sodium reabsorption in normal and injured rat lungs. Am J Respir Crit Care Med. 1997; 155:1777–
1784. [PubMed: 9154891]
66. Dada LA, Sznajder JI. Mechanisms of pulmonary edema clearance during acute hypoxemic
respiratory failure: Role of the Na,K-ATPase. Crit Care Med. 2003; 31(suppl 4):S248–S252.
[PubMed: 12682448]
67. Planes C, Blot-Chabaud M, Matthay MA, et al. Hypoxia and beta 2-agonists regulate cell surface
expression of the epithelial sodium channel in native alveolar epithelial cells. J Biol Chem. 2002;
277:47318–47324. [PubMed: 12372821]
68. Kwak HJ, So JN, Lee SJ, et al. Angiopoietin-1 is an apoptosis survival factor for endothelial cells.
FEBS Lett. 1999; 448:249–253. [PubMed: 10218485]
69. Gamble JR, Drew J, Trezise L, et al. Angiopoietin-1 is an antiperme-ability and anti-inflammatory
agent in vitro and targets cell junctions. Circ Res. 2000; 87:603–607. [PubMed: 11009566]
70. Thurston G, Suri C, Smith K, et al. Leakage-resistant blood vessels in mice transgenically
overexpressing angiopoietin-1. Science. 1999; 286:2511–2514. [PubMed: 10617467]
71. Kim I, Moon SO, Park SK, et al. Angiopoietin-1 reduces VEGF-stimulated leukocyte adhesion to
endothelial cells by reducing ICAM-1, VCAM-1, and E-selectin expression. Circ Res. 2001;
89:477–479. [PubMed: 11557733]
72. Pizurki L, Zhou Z, Glynos K, et al. Angiopoietin-1 inhibits endothelial permeability, neutrophil
adherence and IL-8 production. Br J Pharmacol. 2003; 139:329–336. [PubMed: 12770938]
73. Mason CM, Guery BP, Summer WR, et al. Keratinocyte growth factor attenuates lung leak
induced by alpha-naphthylthiourea in rats. Crit Care Med. 1996; 24:925–931. [PubMed: 8681593]
74. Welsh DA, Summer WR, Dobard EP, et al. Keratinocyte growth factor prevents ventilator-induced
lung injury in an ex vivo rat model. Am J Respir Crit Care Med. 2000; 162(3 pt 1):1081–1086.
[PubMed: 10988134]
75. Birukova AA, Alekseeva E, Mikaelyan A, et al. HGF attenuates thrombin-induced endothelial
permeability by Tiam1-mediated activation of the Rac pathway and by Tiam1/Rac-dependent
inhibition of the Rho pathway. FASEB J. 2007; 21:2776–2786. [PubMed: 17428964]
76. Singleton PA, Salgia R, Moreno-Vinasco L, et al. CD44 regulates hepatocyte growth factor-
mediated vascular integrity. Role of c-met, Tiam1/Rac1, dynamin 2, and cortactin. J Biol Chem.
2007; 282:30643–30657. [PubMed: 17702746]
77. Rubenfeld GD, Caldwell E, Peabody E, et al. Incidence and outcomes of acute lung injury. N Engl
J Med. 2005; 353:1685–1693. [PubMed: 16236739]
78. Gonzalez-Rey E, Anderson P, Gonzalez MA, et al. Human adult stem cells derived from adipose
tissue protect against experimental colitis and sepsis. Gut. 2009; 58:929–939. [PubMed:
19136511]
79. Kim J, Hematti P. Mesenchymal stem cell-educated macrophages: A novel type of alternatively
activated macrophages. Exp Hematol. 2009; 37:1445–1453. [PubMed: 19772890]
80. Nemeth K, Mayer B, Mezey E. Modulation of bone marrow stromal cell functions in infectious
diseases by toll-like receptor ligands. J Mol Med. 2010; 88:5–10. [PubMed: 19756450]
81. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med. 2000; 342:1334–
1349. [PubMed: 10793167]
82. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung
injury and the acute respiratory distress syndrome. The acute respiratory distress syndrome
network. N Engl J Med. 2000; 342:1301–1308. [PubMed: 10793162]
83. Wiedemann HP, Wheeler AP, Bernard GR, et al. Comparison of two fluid-management strategies
in acute lung injury. N Engl J Med. 2006; 354:2564–2575. [PubMed: 16714767]
84. Matthay MA, Thompson BT, Read EJ, et al. Therapeutic potential of mesenchymal stem cells for
severe acute lung injury. Chest. 2010; 138:965–972. [PubMed: 20923800]
85. Larson BL, Ylostalo J, Prockop DJ. Human multipotent stromal cells undergo sharp transition from
division to development in culture. Stem Cells. 2008; 26:193–201. [PubMed: 17916801]
Lee et al. Page 11
Stem Cells. Author manuscript; available in PMC 2012 June 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 1.
In acute lung injury (ALI), the therapeutic properties of mesenchymal stem cells (MSCs)
rely on both paracrine mechanism and through interaction with other cells. Multiple
mechanisms have been identified through which MSC therapy may repair the alveolar
epithelium and endothelium during ALI, such as (a) secretion of paracrine soluble factor,
which restore alveolar fluid clearance, lung permeability, and inhibit bacterial growth, and
(b) immunomodulation of innate and adaptive immune cells, which reduce alveolar
inflammation. Although not fully characterized, the potential of engraftment by in vivo
modified MSCs and the presence of endogenous adult stem cells with characteristics similar
to MSCs may also contribute to this therapeutic effect. Abbreviations: Ang-1,
angiopoietin-1; IL-10, interleukin-10; KGF, keratinocyte growth factor; MSC, mesenchymal
stem cell; PGE2, prostaglandin E2; PMN, polymorphonuclear neutrophils.
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Table 1
Mesenchymal stem cell paracrine soluble factors: Potential role in acute lung injury
Soluble factorsa Functional effects
Keratinocyte growth factor Alveolar fluid transport [3]
Lung protein permeability [4]
Angiopoietin-1 Lung epithelial and endothelial
 permeability [5–7]
Interleukin-1 receptor
 antagonist
Anti-inflammatory [8]
Interleukin-10 Anti-inflammatory [9, 10]
Prostaglandin E2 Anti-inflammatory [9]
LL-37 Antimicrobial [9, 11, 12]
a
Secretion of some soluble factors may depend on cell-cell contact or the alveolar milieu itself, such as interleukin-10 or prostaglandin E2.
Stem Cells. Author manuscript; available in PMC 2012 June 1.
